Why Are Pills Round?

By George ForrestTechnology

The shape of the most-produced manufactured object in human history was decided in 1843. The patient was never in the room.

The round tablet is the QWERTY of medicine — an 1843 industrial decision so deeply locked into modern pharma’s infrastructure that every alternative is structurally disadvantaged before it begins. The case for redesign is on the public record. The industry has not moved. There is a name for that.

(8-minute read)

The Pill You Have Never Looked At

You have swallowed thousands of them. Most readers have never thought about the shape.

A small biconvex disc. Slightly raised on top and bottom. White. Smooth. Familiar enough to feel inevitable.

It is not.

The round tablet is the most-produced manufactured object in human history that has nothing to do with the human who consumes it. It is the product of an industrial decision made in 1843, by a single English inventor solving a single mechanical problem — and the pharmaceutical industry has not seriously revisited the question since.

What a tablet looks like is not what a patient needs. It is what a machine can produce.

It Is Not for You

The story modern pharma tells about the round tablet is that it is convenient for the patient. It is not.

Round tablets are demonstrably harder to swallow than oblong or film-coated equivalents. They are more likely to lodge in the oesophagus, more likely to be aspirated by patients with neurological impairment, and more likely to be cut, crushed, halved, or hidden in food by carers who have run out of other options.

The round tablet is not optimised for the throat, the tongue, the hand, or the perception of dose intuitive to the patient.

It is, however, perfectly optimised for the steel die that produced it.

Joseph Brockedon, 1843

In 1843, an English engineer, painter and amateur mountaineer named Joseph Brockedon filed UK Patent 9977: “Shaping Pills, Lozenges and Black-Lead by Pressure in Dies.”

Before Brockedon, pills were hand-rolled. Each was a small ball of paste, formed by an apothecary or — in the industrial era — by a young woman whose hand-skill set the throughput of an entire pharmacy.

Brockedon’s invention was a pencil-press repurposed. He had been compressing graphite powder into pencil leads since 1819. Pharma was an adjacency. His patent was a cousin of his core business, not the centrepiece of it.

The patent defined three of the assumptions that govern the modern tablet. That medicine should be solid. That solid medicine should be made by compression. And that the geometry of compression should be circular, because dies are easier to machine that way.

Two centuries on, every assumption is still in place.

— · —

The pencil-press won.

— · —

Burroughs Wellcome registered the trademark “Tabloid” in 1884 to describe the new compressed-pill format and built a global pharmaceutical brand on the word. The shape of the medicine became the brand of the medicine, and the brand of the medicine became the medicine itself.

The Voice That Did Speak Up

There is a counterpart to Brockedon. He is less famous than he should be.

In 2012, the formulation scientist Sven Stegemann — whose career spans decades of pharmaceutical industry work in oral dose-form design — published a paper in Ageing Research Reviews titled “Geriatric drug therapy: neglecting the inevitable majority.” It was a public statement that the industry’s dose-form choices had failed the patient population that takes the most medicine. The paper named the geometry. It named the data. It made the case.

In 2017, the European Medicines Agency published a reflection paper titled “Pharmaceutical development of medicines for use in the older population.” It set out, in regulatory text, that age-appropriate medication includes consideration of dose-form acceptability — including shape, size, and ease of swallowing. The paper is still on the EMA website. It has been cited in the formulation-science literature for a decade. The European Society for Swallowing Disorders has issued consensus statements echoing the same conclusion.

The case for redesign is documented. The recommendation is documented. The institutional voice exists.

The industry has not moved.

Which leaves only one question to answer. Why?

Path Dependency: The Round Tablet Is QWERTY in White

The economic theory has a name.

In 1985, the economist Paul David published a paper in the American Economic Review called “Clio and the Economics of QWERTY.” His argument: the standard typewriter keyboard layout — designed in 1873 to slow typists down so the mechanical type-bars would not jam — persisted through every subsequent technological generation despite never being optimal for human fingers. The reason was not technological. It was switching cost.

W. Brian Arthur formalised the idea in a 1994 monograph at the University of Michigan: increasing returns. The more an industry produces a thing, the cheaper that thing becomes, and the more disadvantaged any alternative becomes. Each tooling investment, each regulatory precedent, each consumer expectation is an increment of advantage that any competing standard has to overcome from a standing start.

The round tablet is QWERTY in white.

Tablet manufacturing infrastructure is sunk-cost capital, calibrated since the 1840s to round dies. ICH Q-series tablet stability and dissolution standards were written assuming circular cross-sections. Generic substitution depends on shape recognition: a patient who has taken a round white tablet for ten years does not trust an oval blue one. Tablet press tooling pricing favours round; specialty tooling carries a premium and a shorter punch-life.

None of these facts is decisive on its own. Together, they are an architecture of disadvantage. Every alternative arrives in a market that has been pre-shaped against it.

The shape persists not because it is right. It persists because the industry has compounded the cost of changing it.

What the Patient Was Never Asked

The data is specific. It has been specific for a decade.

A 2013 study by Schiele and colleagues, published in Pharmacotherapy, surveyed 1,051 patients in German general practice. 37.4% reported difficulty swallowing tablets. Of those, 9% had broken or chewed tablets to make them easier — a route alteration that voids the formulation’s controlled-release properties and, in some products, doubles peak plasma concentration.

Tablet shape was a significant predictor. In Stegemann’s reviews of the head-to-head literature, switching from a standard round tablet to a film-coated oblong reduced reported swallowing difficulty by 30 to 50% in geriatric populations — same drug, same dose, same active ingredient. Different shape. Different outcome.

Dysphagia — clinically diagnosed difficulty swallowing — affects roughly 8% of all adults, between 11% and 20% of community-dwelling adults over 65, and between 40% and 60% of nursing-home residents. For these populations, the tablet’s geometry is not a minor inconvenience. It is a determinant of whether the medicine is taken at all.

It is 7am. A woman in her seventies counts out four tablets at the kitchen table. Three are round — the standard NHS dispensary defaults. The largest goes in first; she takes water, and feels it stick midway down. She drinks more water. She tilts her head. She drinks more water. The tablet eventually moves. This is not a rare event. This is a Tuesday morning across millions of households where the dose is not the problem and the shape is not the diagnosis.

— · —

Pharma reformulates the molecule. It does not reformulate the disc.

— · —

The Counter-Arguments That Don’t Solve It

The objections are real. Each fails for the same structural reason.

  • Coated oblong tablets — caplets — improve swallowability. They also inherit the same compression-press infrastructure, the same compression cycle, the same regulatory pathway, the same upstream supply chain. The tooling is incremental. The architecture is not.
  • Capsules are easier to swallow for many patients. They are also a content-stability problem masquerading as a delivery solution: gelatin and HPMC capsules introduce moisture sensitivity, supply-chain complexity, and a higher unit cost. They have not displaced the tablet at scale because they cannot, not because they have not been tried.
  • Orally disintegrating tablets help some populations but are still compressed dose forms. Their bioavailability profiles are largely indistinguishable from conventional tablets in published comparisons. The geometry of the dose form has changed; the architecture has not.
  • Liquid suspensions and syrups solve swallowability. They are confined to a narrow set of indications — paediatric, oncology supportive care, mental-health rescue therapies — and have rarely been adopted for adult chronic primary-care medicines. Not because the chemistry is impossible. Because the manufacturing economics, prescribing habits and pharmacy infrastructure are calibrated to tablets.

Each is a workaround. None is a redesign. The compressed round tablet remains the dominant oral dose form in every developed pharmaceutical market — because the path that led to it has compounded its lead with every decade.

What Comes Next

Here is the falsifiable claim.

By 2030, at least one major regulator — EMA, FDA, MHRA, or PMDA — will require human-factor and patient-acceptability data on tablet form factor as part of New Drug Application or Marketing Authorisation submission. The 2017 EMA reflection paper is the soft signal that this is coming; the 2025 FDA draft guidance on patient-focused drug development extends the trajectory.

The driver is not advocacy. It is liability. As the data on shape-related swallowing harm becomes uncontested, the regulatory case for ignoring it becomes harder to defend. The first regulator that requires the data will be followed by the second within five years and the third within ten.

By 2035, the dominant oral form factor for paediatric, geriatric and chronic-condition therapeutics will not be the round compressed tablet. It will be liquid, dispersed, or printed — formats designed around what the body receives, not what the press can produce. Spritam (levetiracetam, Aprecia Pharmaceuticals) became the first FDA-approved 3D-printed prescription medicine in 2015. It is the existence proof. Personalised geometry can clear regulatory bars.

The structural drivers are three. An ageing population in every developed market — over-65s already represent 19% of the EU and are projected to reach 30% by 2050. Payer pressure on adherence — the WHO has estimated non-adherence costs developed health systems between $100 billion and $300 billion annually, with formulation factors a meaningful contributor. And the bioavailability ceiling that the compressed tablet cannot break through, which is the subject of Ibumix’s earlier essay, The 80% Problem.

Path dependency does not last forever. It lasts until a force outside the path arrives. Three are arriving at once.

The Ibumix Position

The pill is round because the press wanted it round. The patient was never asked. The data shows the patient would have preferred otherwise — and the next era of oral pharma will be defined by formats designed around what the body receives, not what the press can produce.

Ibumix is building those formats. The bet is that the dominant oral medicine of 2035 will not be a circular disc of compressed powder. It will be liquid, dispersed, or printed — and it will reach the bloodstream more reliably, fit the human body more comfortably, and reduce the carbon and waste burden of pharma’s industrial-era inheritance.

The round tablet was the right answer to a question pharma stopped asking. The next answer is being designed now.

Closing

If you have ever tried to swallow a round tablet and felt it resist — caught for a moment between the back of the throat and the top of the oesophagus, refusing to move until you took a second swallow of water — the geometry did that to you on purpose.

Not because anyone wanted you to suffer.

Because no-one in the chain of decisions thought to ask.

A 19th-century pencil-press inventor solving a manufacturing problem. A century of compression-press engineers optimising throughput. A regulatory pathway that codified the shape into law. A pharmacy industry that taught patients to recognise medicine by its geometry. Each decision rational on its own terms. Each decision calibrated to the press, not to you.

Path dependency does not always feel like a choice. The round tablet has not felt like a choice for two centuries.

— · —

The pill is round not because it is perfect — but because it was possible.

— · —

The next pill will not be a pill at all.

Ibumix is a UK-based pharmaceutical platform company developing new liquid drug delivery platforms — designing oral medicines around what the body receives, not what the factory produces.

Sources

Leave a Reply

Your email address will not be published. Required fields are marked *